

assessments are also available by mail through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, or by telephone at (703) 487-4650. A charge is applied by NTIS for these public health assessments. The NTIS order numbers are listed in parentheses after the site name.

#### Public Health Assessments or Addenda Completed or Issued

Between January 1, 1995 and March 31, 1995, public health assessments or addenda to public health assessments were issued for the NPL sites listed below:

#### Alabama

T. H. Agriculture and Nutrition (Montgomery)—Montgomery—(PB95-188967)

#### Colorado

Smelertown/Koppers—Salida—(PB95-195160)

#### Connecticut

Old Southington Landfill—Southington—(PB95-195103)

#### Florida

Agrico Chemical Site—Pensacola—(PB95-181764)

#### Hawaii

Del Monte Corporation (Oahu Plantation)—Kunia (PB95-181814)

#### Idaho

Blackbird Mine—Cobalt—(PB95-171146)

#### Illinois

Wauconda Sand and Gravel Landfill—Wauconda—(PB95-187084)

#### Indiana

Marion Bragg Dump—Marion—(PB95-179867)

Reilly Tar & Chemical Corporation (Indianapolis Plant)—Indianapolis—(PB95-186854)

#### Louisiana

American Creosote Works, Incorporated (Winnfield Plant) Winnfield—(PB95-195186)

#### Massachusetts

Hocomonco Pond—West Borough—(PB95-171518)

Iron Horse Park—Billerica—(PB95-171542)

#### Michigan

South Macomb Disposal Authority #9, 9A—Macomb Township—(PB95-188876)

#### Mississippi

Chemfax—Gulfport—(PB95-195830)  
Potter Company—Wesson—(PB95-171526)

#### Missouri

Weldon Springs Ordnance Works (Former)—St. Charles—(PB95-195178)

#### New Jersey

Bridgeport Rental and Oil Services—Logan Township—(PB95-199402)

Horseshoe Road Dump—Sayreville—(PB95-181939)

Pomona Oaks Well Contamination—Galloway Township (PB95-172854)

Upper Deerfield Township Sanitary Landfill—Upper Deerfield Township—(PB95-187787)

#### New Mexico

AT & SF (Albuquerque)—Albuquerque—(PB95-179917)

#### New York

Johnstown City Landfill—Johnstown—(PB95-199360)

Niagara County Refuse—Wheatfield—(PB95-171534)

#### Oklahoma

National Zinc Company—Bartlesville—(PB95-191649)

Oklahoma Refining Company—Cyril—(PB95-187712)

#### Oregon

Northwest Pipe and Casing Company—Clackamas (PB95-201505)

#### Puerto Rico

Frontera Creek—Rio Abajo—(PB95-179107)

#### South Carolina

Helena Chemical Company Landfill—Fairfax—(PB95-179479)

#### Washington

American Crossarm and Conduit Company—Chehalis (PB95-188942)

#### Wisconsin

Kohler Company Landfill—Kohler—(PB95-179008)

Dated: August 15, 1995.

#### David Satcher,

Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 95-20726 Filed 8-21-95; 8:45 am]

BILLING CODE 4163-70-P

#### Centers for Disease Control and Prevention

[CDC 576]

#### Project Grant to the National Tuberculosis Controllers Association

**SUMMARY:** The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1995 grant funds for a sole source grant to the National Tuberculosis Controllers Association (NTCA). Approximately \$150,000 is available in FY 1995 to fund this grant. The award is expected to begin on or about September 30, 1995, for a 12-month budget period within a five year project period. The funding estimate is subject to change. Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds.

The purpose of this grant is to assist NTCA in developing, establishing, and coordinating systems and procedures to enhance the role of State and local health department tuberculosis (TB) control officials (TB Controllers), TB Nurse Consultants and other key TB program staff, in directing efforts to control, prevent, and eventually eliminate TB in the United States.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority areas of HIV Infection and Immunization and Infectious Diseases. (To order a copy of "Healthy People 2000," see the section "Where to Obtain Additional Information.")

#### Authority

This grant is authorized under Section 317E of the Public Health Service Act (42 U.S.C. 247b-6), as amended. Applicable program regulations are found in part 51b, subparts A, of Title 42, Code of Federal Regulations.

#### Smoke-Free Workplace

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the non-use of all tobacco products, and Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

**Eligible Applicant**

Assistance will be provided only to NTCA for this project. No other applications are solicited.

Eligibility is limited to NTCA because of its existing unique relationship with the State and local TB Controllers, TB Nurse Consultants, and other key TB program staff. NTCA is the only national TB organization whose members are TB Controllers, TB Nurse Consultants, and other key TB program staff who represent all States and territories. NTCA was organized in January 1995 to advance the elimination of TB in the United States through collective, concerted actions of the officials of State, local, and territorial governments who are empowered by their jurisdictions with the responsibility for carrying out programs to control and prevent TB. NTCA's technical expertise is an asset in the complex and changing environment of front-line health care delivery.

**Executive Order 12372 Review**

This application is not subject to review as governed by Executive Order 12372, Intergovernmental Review of Federal Programs.

**Public Health System Reporting Requirements**

This program is not subject to the Public Health System Reporting Requirements.

**Catalog of Federal Domestic Assistance Number**

The Catalog of Federal Domestic Assistance Number is 93.947, TB Demonstration, Research, Public and Professional Education Projects.

**Where to Obtain Additional Information**

If you are interested in obtaining additional information regarding this project, please refer to announcement 576 and contact Manuel Lambrinos, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, N.E., Room 300, Mailstop E-16, Atlanta, GA 30305, telephone (404) 842-6777.

A copy of "Healthy People 2000" (Full Report, Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report, Stock No. 017-001-00473-1) referenced in the **SUMMARY** may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: August 15, 1995.

**Joseph R. Carter,**

*Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 95-20624 Filed 8-21-95; 8:45 am]

BILLING CODE 4163-18-P

**Food and Drug Administration****Advisory Committees; Notice of Meetings**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

**MEETINGS:** The following advisory committee meetings are announced:

**Generic Drugs Advisory Committee**

*Date, time, and place.* September 6 and 7, 1995, 8:30 a.m., Holiday Inn—Gaithersburg, Two Montgomery Village Ave., Gaithersburg, MD.

*Type of meeting and contact person.* Open committee discussion, September 6, 1995, 8:30 a.m. to 11 a.m.; open public hearing, 11 a.m. to 12 m., unless public participation does not last that long; open committee discussion, 12 m. to 5 p.m.; open committee discussion, September 7, 1995, 8:30 a.m. to 12 m.; closed committee deliberations, 12 m. to 5 p.m.; Kimberly L. Topper or Angie Whitacre, Center for Drug Evaluation and Research (HFD-9), Food and Drug

Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Generic Drugs Advisory Committee, code 12539.

*General function of the committee.*

The committee gives advice on scientific and technical issues concerning the safety and effectiveness of human generic drug products for use in the treatment of a broad spectrum of human diseases and makes appropriate recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, the Commissioner of Food and Drugs, and the Director of the Center for Drug Evaluation and Research. The committee may also review agency-sponsored intramural and extramural biomedical research programs in support of FDA's generic drugs regulatory responsibilities.

*Agenda—Open public hearing.*

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before August 22, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

*Open committee discussion.* On September 6 and 7, 1995, the committee will review and advise on the status of Center for Drug Evaluation and Research (CDER) quality and performance initiatives related to formulation dissolution and bioequivalence. The committee will also discuss its relationship to, and interaction with, CDER's new Office of Pharmaceutical Sciences.

*Closed committee deliberations.* On September 7, 1995, the committee will discuss trade secret and/or confidential commercial information relevant to pending abbreviated new drug applications (ANDA's). This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

**Radiological Devices Panel of the Medical Devices Advisory Committee**

*Date, time, and place.* September 11, 1995, 9:30 a.m., Corporate Bldg., conference room 20B, 9200 Corporate Blvd., Rockville, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Marriott